|Day's Range||121.80 - 122.30|
|52 Week Range||103.65 - 123.59|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer. New Jersey-based J&J has been battling a series of lawsuits over its talc-based products, including Johnson's Baby Powder, brought by around 5,950 women and their families. The company denies any link between talc and cancer.
The drug, whose generic name is brolucizumab, aims to treat neovascular age-related macular degeneration (nAMD), the leading cause of severe vision loss and blindness in people over the age of 65 in North America, Europe, Australia and Asia. Head-to-head late-stage trials showed RTH258 worked as well as Regeneron's Eylea, developed with Bayer. This was achieved with over half the patients dosed every 12 weeks compared to every eight weeks with Eylea.
DuPont and Dow Chemical Co have won U.S. antitrust approval to merge on condition that the companies sell certain crop protection products and other assets, according to a court filing on Thursday. The asset sales required by U.S. antitrust enforcers were similar to what the companies had agreed to give up in a deal they struck with European regulators in March. The deal is one of several big mergers by farm suppliers, and the antitrust approval was quickly denounced by the head of the National Farmers Union, saying that farmers would face higher costs.